Garret A. FitzGerald
Garret A. FitzGerald is a renowned pharmacologist and physician-scientist known for his significant contributions to the field of cardiovascular disease research. He is currently the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania, where he has been instrumental in the development of novel therapeutic strategies for the treatment of cardiovascular diseases.
Early Life and Education[edit | edit source]
Garret A. FitzGerald was born in Dublin, Ireland. He completed his medical degree at the University College Dublin, where he developed a keen interest in pharmacology and translational medicine. He then moved to the United States for his postgraduate training, where he specialized in Internal Medicine and Cardiology.
Career[edit | edit source]
FitzGerald's career has been marked by his innovative research in the field of cardiovascular pharmacology. He is best known for his work on the role of prostaglandins and other eicosanoids in cardiovascular disease. His research has led to the development of new drugs and therapeutic strategies for the treatment of heart disease, stroke, and other cardiovascular conditions.
In addition to his research, FitzGerald has also made significant contributions to medical education. He has mentored numerous students and young researchers, many of whom have gone on to have successful careers in academia and industry.
Awards and Honors[edit | edit source]
Over the course of his career, FitzGerald has received numerous awards and honors in recognition of his contributions to medicine and science. These include the Prince Mahidol Award for Medicine, the Grand Prix Scientifique de la Fondation Lefoulon-Delalande, and the American Heart Association's Research Achievement Award.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
